Jean M. Lewis

Jean M. Lewis

Auto-generated profile, based on publicly available information

Jean M. Lewis

Biological Dynamics, Inc., San Diego, CA, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2018 in ACS Nano
Verified
Journal Article
Closed access
JLJean M. Lewis
Jean M. Lewis
AVAnkit D. Vyas
Ankit D. Vyas
YQYuqi Qiu
Yuqi Qiu
KMKaren S. Messer
Karen S. Messer
RWRebekah White
Rebekah White
MHMichael J. Heller
Michael J. Heller

17 March 2022 in Communications Medicine
Verified
Journal Article
Open access
PDF file
JHJuan Pablo Hinestrosa
Juan Pablo Hinestrosa
RKRazelle Kurzrock
Razelle Kurzrock
JLJean M. Lewis
Jean M. Lewis
NSNicholas Schork
Nicholas Schork
GSGregor Schroeder
Gregor Schroeder
RKRajaram Krishnan
Rajaram Krishnan
Background: Detecting cancer at early stages significantly increases patient survival rates. Because lethal solid tumors often produce few symptoms before progressing to advanced, metastatic disease, diagnosis frequently occurs when surgical resection is no longer curative. One promising approach to detect early-stage, curable cancers uses biomarkers present in circulating extracellular vesicles (EVs). To explore the feasibility of this approach, we developed an EV-based blood biomarker classifier from EV protein profiles to detect stages I and II pancreatic, ovarian, and bladder cancer. Methods: Utilizing an alternating current electrokinetics (ACE) platform to purify EVs from plasma, we use multi-marker EV-protein measurements to develop a machine learning algorithm that can discriminate cancer cases from controls. The ACE isolation method requires small sample volumes, and the streamlined process permits integration into high-throughput workflows. Results: In this case-control pilot study, comparison of 139 pathologically confirmed stage I and II cancer cases representing pancreatic, ovarian, or bladder patients against 184 control subjects yields an area under the curve (AUC) of 0.95 (95% CI: 0.92 to 0.97), with sensitivity of 71.2% (95% CI: 63.2 to 78.1) at 99.5% (97.0 to 99.9) specificity. Sensitivity is similar at both early stages [stage I: 70.5% (60.2 to 79.0) and stage II: 72.5% (59.1 to 82.9)]. Detection of stage I cancer reaches 95.5% in pancreatic, 74.4% in ovarian (73.1% in Stage IA) and 43.8% in bladder cancer. Conclusions: This work demonstrates that an EV-based, multi-cancer test has potential clinical value for early cancer detection and warrants future expanded studies involving prospective cohorts with multi-year follow-up.

19 October 2023 in Communications Medicine
Verified
Journal Article
Open access
PDF file
JHJuan Pablo Hinestrosa
Juan Pablo Hinestrosa
RSRosalie C. Sears
Rosalie C. Sears
HDHarmeet Dhani
Harmeet Dhani
JLJean M. Lewis
Jean M. Lewis
GSGregor Schroeder
Gregor Schroeder
PBPaul R. Billings
Paul R. Billings
Background: Pancreatic ductal adenocarcinoma (PDAC) has an overall 5-year survival rate of just 12.5% and thus is among the leading causes of cancer deaths. When detected at early stages, PDAC survival rates improve substantially. Testing high-risk patients can increase early-stage cancer detection; however, currently available liquid biopsy approaches lack high sensitivity and may not be easily accessible. Methods: Extracellular vesicles (EVs) were isolated from blood plasma that was collected from a training set of 650 patients (105 PDAC stages I and II, 545 controls). EV proteins were analyzed using a machine learning approach to determine which were the most informative to develop a classifier for early-stage PDAC. The classifier was tested on a validation cohort of 113 patients (30 PDAC stages I and II, 83 controls). Results: The training set demonstrates an AUC of 0.971 (95% CI = 0.953–0.986) with 93.3% sensitivity (95% CI: 86.9–96.7) at 91.0% specificity (95% CI: 88.3–93.1). The trained classifier is validated using an independent cohort (30 stage I and II cases, 83 controls) and achieves a sensitivity of 90.0% and a specificity of 92.8%. Conclusions: Liquid biopsy using EVs may provide unique or complementary information that improves early PDAC and other cancer detection. EV protein determinations herein demonstrate that the AC Electrokinetics (ACE) method of EV enrichment provides early-stage detection of cancer distinct from normal or pancreatitis controls.

13 November 2024 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
JLJean M Lewis
Jean M Lewis
DHDorathy-Ann Harris
Dorathy-Ann Harris
JKJanell Kosmatka
Janell Kosmatka
EMEmily Mikrut
Emily Mikrut
JEJack Evenson
Jack Evenson
PBPaul R Billings
Paul R Billings
Background: Blood tests for Alzheimer's disease (AD) that measure biomarkers related to neuropathology have demonstrated to be useful, minimally-invasive ways to identify patients for screening into clinical trials. While some AD biomarkers can be detected in plasma, greater sensitivity is needed to make plasma AD tests more effective. Extracellular vesicles (EVs) in plasma carry AD-related biomarkers from the brain and could offer a concentrated source of brain-related biomarkers, though the methodological complexities involved in isolating plasma EVs have hampered its validation for clinical use. Objective: To explore the feasibility and effectiveness of developing blood tests for AD utilizing extracellular vesicle-bound protein biomarkers. Methods: We developed a simplified method for isolating EVs directly from plasma using an alternating current electrokinetic (ACE) microchip. No sample pretreatment steps were needed. Protein biomarkers on the EVs were detected by adding fluorescent antibodies to the plasma samples before capture by the chip. This allowed measurement of EV biomarker levels directly on the chip. Results: AD or non-AD control plasma was measured for ten different AD-related biomarkers. EV-associated NCAM1, pTau231, α-synuclein, and TDP-43 levels were able to distinguish a group of 10 AD, 10 mild cognitive impairment (MCI), and 10 non-AD subjects. pTau231 was different between AD and non-AD (p = 0.0300) and α-synuclein differentiated AD from MCI (p = 0.0148). Conclusions: This study shows how ACE microfluidic chip technology can help differentiate AD and MCI patients from non-AD controls with clinical relevance. This work also highlights the important diagnostic role of plasma EV biomarkers in neurodegenerative disease.

4 April 2023 in Cancer Research
Verified
Journal Article
Closed access
JHJuan P. Hinestrosa
Juan P. Hinestrosa
HDHarmeet Dhani
Harmeet Dhani
GSGregor Schroeder
Gregor Schroeder
JLJean M. Lewis
Jean M. Lewis
HBHeath I. Balcer
Heath I. Balcer
PBPaul Billings
Paul Billings
Introduction Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer and is one of the deadliest cancer in the U.S., with a 5-year survival rate of just 11%. It is expected that ~62,000 new cases will be diagnosed in the US in 2023 and >70% of those will be at the regional or distant state, when curative resection is no longer an option. It is imperative that tools enabling early disease detection (stages I and II) are developed to improve patient survival outcomes. Here, we report the results of a study on the utility of extracellular vesicles (EVs) for early PDAC detection. Methods Our case-control training set was comprised of 75 pathologically confirmed PDAC cases (Stage I = 31, Stage II = 44) and 640 controls (including 11 subjects with pancreatitis) for EV biomarker and algorithm selection via machine learning. EVs from plasma were isolated using a proprietary technology, then EV-bound proteins of interest were analyzed via an immunoassay. A second independently collected cohort of 20 confirmed PDAC cases (Stage I = 10, Stage II = 10) and 27 controls (including 9 patients newly diagnosed with diabetes) was used for validation. Results The machine learning analysis using EV-isolated proteins generated a signature that utilized 8 different biomarkers, with an AUC of 0.989 (95% CI: 0.980 - 0.998) in the training set and an AUC of 0.987 (CI: 0.964 - 1.000) in the validation set. For the validation set, the sensitivity was 95% (CI: 76.4% - 99.1%) and the specificity was 92.6% (CI: 76.6% - 97.9%), with 10 out of 10 stage I cases and 9 out of 10 stage II cases correctly classified. Conclusions The ability to alter the future outcomes of PDAC patients will be predicated on development of a new generation of early-detection biomarkers and technologies. The use of EV protein signatures, a new class of cell-free biomarker, permits detection at high sensitivity and specificity, as demonstrated for the independently collected validation cohort. Studies aimed to assess this test for high-risk patients (family history of PDAC, known germline mutations, precursor lesions, hereditary pancreatitis, new onset diabetes will continue towards the establishment of real-world evidence. Citation Format: Juan P. Hinestrosa, Harmeet Dhani, Gregor Schroeder, Jean M. Lewis, Heath I. Balcer, Razelle Kurzrock, Dove Keith, Rosalie Sears, Paul Billings. Pancreatic ductal adenocarcinoma (PDAC) early detection. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6515.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
JHJuan P. Hinestrosa
Juan P. Hinestrosa
JLJean M. Lewis
Jean M. Lewis
DSDavid J. Searson
David J. Searson
HBHeath I. Balcer
Heath I. Balcer
DGDavid J. Gonzalez
David J. Gonzalez
RKRajaram Krishnan
Rajaram Krishnan
In this study, we evaluated the ability to detect novel proteins on extracellular vesicles (EVs) following isolation using an alternating current electrokinetic (ACE) microarray. EVs circulating in blood contain a wealth of biomarkers that are thought to reflect the tumor’s proteome; however, detecting the full diversity of EV proteins may depend on choice of method to purify EVs for analysis. We compared an ACE microarray isolation method with a conventional chemical precipitation method to isolate EVs from blood plasma cancer and control samples. EVs were isolated from 1 mL each of control or pancreatic cancer patient plasma using the ExoVerita platform (Biological Dynamics) or ExoQuick Ultra kit (System Biosciences). Purified EVs were processed using tandem mass tag (TMT)-based multiplexing mass spectrometry proteomics (ThermoFisher Scientific) and the resulting peptide spectra were analyzed and quantified to determine the proteins present. Additional analyses, such as bioanalyzer measurements of contaminating plasma proteins and nanoparticle tracking analysis were performed in parallel to further characterize the isolated EVs. Cancer EVs isolated by ACE were enriched in proteins related to cancer functions when compared to non-cancer control EVs. They also showed enrichment in ontology clusters such as NABA core matrisome proteins, with depressed expression of wound healing family proteins. In contrast, EVs isolated using chemical purification demonstrated enrichment chiefly in proteins functionally grouped into immune system or blood regulation functions. After analyzing EVs isolated by ACE, a total of fifty-one (51) proteins were observed to be upregulated in the cancer donor samples. EV isolation method choice significantly impacted the proteomic profile observed. EV isolation using ACE-based technology can provide more insights into understanding the proteome by possibly reducing or removing non-specific proteins from the EVs. With better separation of EVs from blood proteins, the EV proteins identified may have greater biological significance. Citation Format: Juan P. Hinestrosa, Jean M. Lewis, David J. Searson, Heath I. Balcer, David J. Gonzalez, Rajaram Krishnan. Proteomic analysis of extracellular vesicles from oncology donor samples purified using an alternating current electrokinetic microelectrode chip [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5082.